8-K: Aquestive Therapeutics Reports Positive Q1 Results, Advances Key Pipeline Programs

Aquestive Therapeutics announced positive first quarter 2024 financial results, highlighted by the successful completion of a Phase 3 study for Anaphylm and FDA approval for Libervant in younger pediatric patients.

Summary

• Aquestive Therapeutics reported its first quarter 2024 financial results, showing an 8% increase in total revenue to $12.1 million compared to $11.1 million in the same period last year.
• The revenue growth was primarily driven by a 30% increase in manufacturing and supply revenue, excluding a one-time retroactive price increase from 2022, and a 23% increase in license and royalty revenue.
• Research and development expenses increased to $5.9 million, up from $3.5 million in the first quarter of 2023, due to the advancement of the Anaphylm program.
• Selling, general, and administrative expenses rose to $10.7 million, compared to $7.5 million in the prior year, including $1.7 million in one-time severance costs.
• The company reported a net loss of $12.8 million, or $0.17 per share, compared to a net income of $8.1 million in the first quarter of 2023, primarily due to a one-time income in 2023 and increased operating expenses.
• Non-GAAP adjusted EBITDA loss was $7.2 million, compared to a loss of $3.9 million in the first quarter of 2023.
• Aquestive completed a $77.5 million underwritten public offering, extending their cash runway into 2026 and ending the quarter with $95.2 million in cash and cash equivalents.
• The company is targeting an Anaphylm New Drug Application (NDA) submission to the FDA by the end of 2024.
• Aquestive received FDA approval for Libervant for patients aged two to five years, and the product is now available for non-Medicaid prescriptions.
• The company manufactured approximately 42 million doses of products in the first quarter of 2024, compared to 33 million doses in the first quarter of 2023.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments such as the successful Phase 3 trial for Anaphylm, FDA approval for Libervant, and a strong capital raise, the company also reported a significant net loss and increased operating expenses. The sentiment is cautiously optimistic, with potential for future growth but also significant risks.

Positives

• The successful completion of the Anaphylm Phase 3 study is a significant milestone.
• FDA approval of Libervant for young children provides a new treatment option.
• The $77.5 million capital raise significantly strengthens the company's financial position.
• The company is on track to submit the Anaphylm NDA by the end of 2024.
• The increase in manufacturing and royalty revenue indicates strong demand for Aquestive's products.
• The company has extended its cash runway into 2026.
• Positive results from the first-in-human study for AQST-108 were achieved.
• The company has addressed FDA concerns regarding Anaphylm, removing product hold time from administration instructions.
• Aquestive continues to see consistent order demand for the manufacturing of Indivior's Suboxone product.
• The company is actively progressing its Adrenaverse platform with AQST-108.

Negatives

• The company reported a net loss of $12.8 million for the first quarter of 2024.
• Selling, general, and administrative expenses increased significantly, including one-time severance costs.
• Non-GAAP adjusted EBITDA loss was $7.2 million, compared to a loss of $3.9 million in the first quarter of 2023.
• The company's net loss was primarily driven by a one-time income in 2023 and increased operating expenses.
• Research and development expenses increased due to the advancement of the Anaphylm program.
• The company is subject to an orphan drug market exclusivity block for Libervant in older patients until January 2027.
• The company's net loss was primarily driven by a one-time $14.5 million of other income recognized in the first quarter 2023.

Risks

• There are risks associated with the development and regulatory approval of Anaphylm and other product candidates.
• The company faces risks related to the commercialization of new products, including market acceptance and competition.
• Aquestive may not be able to overcome the orphan drug exclusivity for Libervant in older patients.
• The company's manufacturing capabilities may not be sufficient to meet demand for its products.
• There is a risk of eroding market share for Suboxone, which accounts for a substantial part of current revenue.
• The company faces risks related to litigation, intellectual property, and regulatory changes.
• There are risks related to the company's debt obligations and financial covenants.
• The company is subject to risks related to cybersecurity and data accessibility disruptions.
• There are risks related to the impact of the COVID-19 global pandemic and other pandemic diseases on the business.
• The company faces risks related to general economic, political, business, industry, regulatory, financial and market conditions.

Future Outlook

Aquestive expects total revenue between $48 to $51 million and a non-GAAP adjusted EBITDA loss between $22 to $26 million for the full year 2024. The company is targeting an Anaphylm NDA submission by the end of 2024 and plans to commence a pediatric study in the second half of 2024.

Management Comments

• Daniel Barber, Chief Executive Officer of Aquestive, stated that the company continues to successfully execute on its growth strategy.
• Mr. Barber highlighted the reduction in cash burn, debt refinancing, strengthened cash position, and successful completion of the Anaphylm Phase 3 study.
• Management is focused on executing the remaining Anaphylm pre-submission studies, developing commercial infrastructure, and efficiently launching Libervant.

Industry Context

This announcement comes as the pharmaceutical industry continues to focus on innovative drug delivery methods and treatments for conditions like anaphylaxis and epilepsy. Aquestive's sublingual and buccal film technologies offer alternatives to traditional injections and nasal sprays, potentially improving patient compliance and outcomes. The company's progress with Anaphylm and Libervant positions it to compete in the market for treatments for severe allergic reactions and seizure clusters.

Comparison to Industry Standards

• Aquestive's Anaphylm is being developed as an alternative to EpiPen and other epinephrine auto-injectors, which are the current standard of care for anaphylaxis. The company's sublingual film technology aims to provide a more patient-friendly option.
• Libervant is positioned as an alternative to device-based products like rectal gels and nasal sprays for treating seizure clusters in young children. The buccal film offers a potentially easier and more convenient administration method.
• The company's manufacturing output of 42 million doses in Q1 2024 is a significant increase compared to 33 million doses in Q1 2023, indicating strong demand for its products.
• Aquestive's revenue growth of 8% year-over-year is a positive sign, but the company's net loss highlights the challenges of drug development and commercialization.
• The company's cash position of $95.2 million is relatively strong compared to other small-cap biotech companies, providing a runway for further development and commercialization efforts.

Stakeholder Impact

• Shareholders will benefit from the strengthened cash position and progress in the product pipeline.
• Employees may experience changes due to the company's growth and restructuring efforts.
• Patients will have access to new treatment options for anaphylaxis and seizure clusters.
• Customers will continue to receive manufactured products through licensing and supply collaborations.
• Suppliers will continue to provide materials for the company's manufacturing operations.
• Creditors will be impacted by the company's debt obligations and financial performance.

Next Steps

• Aquestive will complete the Anaphylm temperature/pH study in the second quarter of 2024.
• The company will complete the Anaphylm self-administration and allergen exposure studies in the third quarter of 2024.
• A pediatric study for Anaphylm is planned to commence in the second half of 2024.
• A pre-NDA meeting with the FDA is targeted for the second half of 2024.
• Aquestive aims to file the NDA for Anaphylm with the FDA by the end of 2024.
• The company will continue to engage with the FDA on Libervant's approval for U.S. market access in patients twelve years of age and older.
• Further clinical studies on AQST-108 are expected in the second half of 2024.

Key Dates

Keywords

Anaphylm, Libervant, epinephrine, diazepam, sublingual film, buccal film, FDA approval, pharmaceuticals, clinical trials, NDA, revenue, EBITDA, public offering, seizure, allergy